- Home
- Products
- Services
- Resources
- About Us
- News
- Contact
The MSS Reference Standard Genomic DNA Cancer Test is a highly characterized genomic DNA (gDNA) reference material designed to validate microsatellite stability (MSS) detection assays in cancer diagnostics. Derived from well-characterized cell lines with confirmed microsatellite stable phenotypes, this standard provides a gold-standard control for verifying the performance of MSI/MSS classification workflows. With comprehensive validation across qPCR, fragment analysis, and NGS platforms, it enables clinical laboratories to ensure accurate identification of microsatellite stable tumors, which is critical for guiding immunotherapy decisions and prognostic assessments .
The standard contains DNA from cell lines with intact mismatch repair (MMR) systems, exhibiting stable microsatellite loci across all 5 recommended markers (BAT25, BAT26, D5S346, D2S123, and D17S250). Each marker’s stability is verified by >1000x NGS coverage, ensuring confidence in assay validation .
Supplied at 30 ng/μL in Tris-EDTA buffer (pH 8.0), the gDNA is provided in convenient 1 μg aliquots, allowing flexible dilution to match clinical sample concentrations. This enables realistic simulation of various input amounts encountered in routine testing .
Validated for compatibility with all major MSI detection methodologies, including:
• Multiplex qPCR-based fragment analysis
• Targeted NGS panels
• Immunohistochemistry (IHC) for MMR proteins
• Capillary electrophoresis systems
Use the standard to establish baseline MSS profiles for your detection platform. Run in triplicate alongside patient samples to verify that microsatellite loci exhibit consistent lengths within the expected range for stable alleles.
Incorporate the standard into method validation studies to:
• Determine assay specificity for MSS classification
• Establish run-to-run reproducibility
• Verify no cross-reactivity with MSI-H samples
• Calibrate interpretation thresholds for MSI calling
Store at -20°C for long-term stability (36 months) or at 4°C for up to 6 months. Avoid repeated freeze-thaw cycles by aliquoting upon first use. Dilute to working concentration (typically 5-20 ng/μL) using molecular biology-grade water or TE buffer .
The standard is derived from characterized colon adenocarcinoma cell lines with confirmed MSS status and intact MMR protein expression (MLH1, MSH2, MSH6, and PMS2). Exact cell line information is provided in the certificate of analysis.
By providing a consistent MSS reference, the standard ensures that MSI classification remains uniform across multi-site clinical trials, reducing inter-laboratory variability in patient stratification for immunotherapy eligibility .
Yes, the standard is optimized for use with targeted NGS panels. Its high-quality gDNA generates consistent coverage across microsatellite loci, enabling accurate assessment of panel performance .
While FFPE-based controls assess the entire workflow including fixation effects, this gDNA standard focuses specifically on the molecular detection phase, allowing laboratories to isolate and troubleshoot amplification and detection steps .
Cat.No. | ID | MSI Status | Format | Quantity | Buffer | Storage Conditions | Details |
CBP80002-1 | MSS-1 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ | |
CBP80002-2 | MSS-2 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ | |
CBP80002-3 | MSS-3 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ | |
CBP80002-4 | MSS-4 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ |
Method | Test content | Advantages | Disadvantages |
IHC | Detects 4 known MMR proteins (MLH1, MSH2, MSH6, and PMS2) | Low price, simple and fast operation | 1) It is possible to miss some abnormalities caused by other MMR proteins |
PCR | Detection of BAT25, BAT26, D2S123, D5S346 and D17S250 loci | 1)The gold standard for testing | 1)High requirements for laboratory conditions |
NGS | Capable of sequencing hundreds of thousands to millions of gene molecules at one time | 1) High throughput, high sensitivity | Subsequent data analysis is difficult |
The MSS Reference Standard Genomic DNA Cancer Test is a highly characterized genomic DNA (gDNA) reference material designed to validate microsatellite stability (MSS) detection assays in cancer diagnostics. Derived from well-characterized cell lines with confirmed microsatellite stable phenotypes, this standard provides a gold-standard control for verifying the performance of MSI/MSS classification workflows. With comprehensive validation across qPCR, fragment analysis, and NGS platforms, it enables clinical laboratories to ensure accurate identification of microsatellite stable tumors, which is critical for guiding immunotherapy decisions and prognostic assessments .
The standard contains DNA from cell lines with intact mismatch repair (MMR) systems, exhibiting stable microsatellite loci across all 5 recommended markers (BAT25, BAT26, D5S346, D2S123, and D17S250). Each marker’s stability is verified by >1000x NGS coverage, ensuring confidence in assay validation .
Supplied at 30 ng/μL in Tris-EDTA buffer (pH 8.0), the gDNA is provided in convenient 1 μg aliquots, allowing flexible dilution to match clinical sample concentrations. This enables realistic simulation of various input amounts encountered in routine testing .
Validated for compatibility with all major MSI detection methodologies, including:
• Multiplex qPCR-based fragment analysis
• Targeted NGS panels
• Immunohistochemistry (IHC) for MMR proteins
• Capillary electrophoresis systems
Use the standard to establish baseline MSS profiles for your detection platform. Run in triplicate alongside patient samples to verify that microsatellite loci exhibit consistent lengths within the expected range for stable alleles.
Incorporate the standard into method validation studies to:
• Determine assay specificity for MSS classification
• Establish run-to-run reproducibility
• Verify no cross-reactivity with MSI-H samples
• Calibrate interpretation thresholds for MSI calling
Store at -20°C for long-term stability (36 months) or at 4°C for up to 6 months. Avoid repeated freeze-thaw cycles by aliquoting upon first use. Dilute to working concentration (typically 5-20 ng/μL) using molecular biology-grade water or TE buffer .
The standard is derived from characterized colon adenocarcinoma cell lines with confirmed MSS status and intact MMR protein expression (MLH1, MSH2, MSH6, and PMS2). Exact cell line information is provided in the certificate of analysis.
By providing a consistent MSS reference, the standard ensures that MSI classification remains uniform across multi-site clinical trials, reducing inter-laboratory variability in patient stratification for immunotherapy eligibility .
Yes, the standard is optimized for use with targeted NGS panels. Its high-quality gDNA generates consistent coverage across microsatellite loci, enabling accurate assessment of panel performance .
While FFPE-based controls assess the entire workflow including fixation effects, this gDNA standard focuses specifically on the molecular detection phase, allowing laboratories to isolate and troubleshoot amplification and detection steps .
Cat.No. | ID | MSI Status | Format | Quantity | Buffer | Storage Conditions | Details |
CBP80002-1 | MSS-1 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ | |
CBP80002-2 | MSS-2 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ | |
CBP80002-3 | MSS-3 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ | |
CBP80002-4 | MSS-4 | MSS | Genomic DNA | 1ug+1ug | Tris-EDTA | 2~8℃ |
Method | Test content | Advantages | Disadvantages |
IHC | Detects 4 known MMR proteins (MLH1, MSH2, MSH6, and PMS2) | Low price, simple and fast operation | 1) It is possible to miss some abnormalities caused by other MMR proteins |
PCR | Detection of BAT25, BAT26, D2S123, D5S346 and D17S250 loci | 1)The gold standard for testing | 1)High requirements for laboratory conditions |
NGS | Capable of sequencing hundreds of thousands to millions of gene molecules at one time | 1) High throughput, high sensitivity | Subsequent data analysis is difficult |
